What we're reading, July 27, 2016: UnitedHealth and Aetna are looking to join California's Medicaid program; the World Health Organization is considering removing transgender identity from list of mental disorders; and medical schools rethink how to treat addiction.
Next year, UnitedHealth and Aetna both plan to join California’s Medicaid program, Medi-Cal, in San Diego and Sacramento. The vast majority (80%) of people covered by Medi-Cal are in managed care plans, and with the program covering one-third of all Californians, the program is almost impossible to ignore, reported California Healthline. There are currently 2 insurers in Medi-Cal managed care and the last new insurer to join was Centene in 2013.
The World Health Organization (WHO) is considering removing transgender identity from the list of mental disorders. According to The New York Times, the change has already been approved by each committee that has considered it, and it is under review for the next edition of the WHO codebook. Removing transgender identity from the mental disorder list helps to reduce some of the stigma; however, the diagnosis won’t be removed entirely from the codebook, because having a code is sometimes the only way patients can receive care.
With the opioid epidemic in the United States, medical schools are retooling their curriculums to address the issue. NPR has highlighted the way some medical schools are changing how they teach about addiction. However, recruiting doctors to specialize in addiction medicine remains a challenge as the field has low reimbursement rates and patients can be difficult to handle.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More